AHCYL1 Fusion

CI-VAR-00001205Explore in graph →CIViC 783

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cholangiocarcinoma2
FGFR2::AHCYL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID1847 Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 f… (full text at CIViC) PMID 24122810 · Arai et al., 2014 · Open in CIViC	civic
FGFR2::AHCYL1 Fusion	Infigratinib + PD173074Substitutes	Predictive	D	Supports Sensitivity Response	3	accepted	EID1853 Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ39… (full text at CIViC) PMID 24122810 · Arai et al., 2014 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Intrahepatic Cholangiocarcinoma1
FGFR2::AHCYL1 Fusion	Erdafitinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID13164 In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-AHCYL1 fusion achieved a partial response to erdafitinib, with a 66.7% maximum reduction in… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic